A 43-year-old African American man presented with burning, hyperpigmented scaling patches on his face, chest, and back for 18 months. Previous biopsies and treatments for conditions like cutaneous lupus erythematosus were ineffective. A new biopsy found intercellular IgG staining in the epidermis consistent with pemphigus foliaceus (PF), which was confirmed by positive anti-desmoglein antibodies. The patient was given rituximab therapy and showed marked improvement. PF is an autoimmune disorder caused by antibodies against desmoglein-1, typically presenting with thick scaling without blisters on the face and trunk.
central nervous infection for clinical pharmacists and other medical students this contains management of cns infections how it can be diagnosed and how to chose appropriate drug treatment based on age of patient.
Ocular involvement in HIV could be caused by opportunistic infections, vascular abnormalities, neoplasms, neuro-ophthalmic conditions, and adverse effects of medications.
Ocular involvement in HIV infection occurs most commonly due to opportunistic infections and neoplasms. But also can be due to drug related and direct infections.
Opportunistic infections like CMV retinitis occur with a significantly reduced CD4 T-cell count and are one of the common causes of blindness in HIV patients.
Unlike other diseases, ocular infection in these immunosuppressed patients is associated with minimal inflammatory signs.
HIV has been isolated from tears, cornea, vitreous, and chorioretinal tissue in affected persons.
The ocular structures affected by HIV include the adnexa, anterior segment, posterior segment, and orbit.
Neuro ophthalmological manifestations also may be seen.
The institution of highly active antiretroviral therapy (HAART) has caused a dramatic improvement in the immune status of HIV-infected individuals and a change in the clinical presentation and course of opportunistic infections.
central nervous infection for clinical pharmacists and other medical students this contains management of cns infections how it can be diagnosed and how to chose appropriate drug treatment based on age of patient.
Ocular involvement in HIV could be caused by opportunistic infections, vascular abnormalities, neoplasms, neuro-ophthalmic conditions, and adverse effects of medications.
Ocular involvement in HIV infection occurs most commonly due to opportunistic infections and neoplasms. But also can be due to drug related and direct infections.
Opportunistic infections like CMV retinitis occur with a significantly reduced CD4 T-cell count and are one of the common causes of blindness in HIV patients.
Unlike other diseases, ocular infection in these immunosuppressed patients is associated with minimal inflammatory signs.
HIV has been isolated from tears, cornea, vitreous, and chorioretinal tissue in affected persons.
The ocular structures affected by HIV include the adnexa, anterior segment, posterior segment, and orbit.
Neuro ophthalmological manifestations also may be seen.
The institution of highly active antiretroviral therapy (HAART) has caused a dramatic improvement in the immune status of HIV-infected individuals and a change in the clinical presentation and course of opportunistic infections.
Introduction: malignant syphilis is an uncommon form of secondary syphilis.This presentation usually occurs in immunocompromised patients, especially in those ones infected by human immunodeficiency virus (HIV). However, it is known that it might exceptionally affect individuals with normal immune response.
Introduction: malignant syphilis is an uncommon form of secondary syphilis.This presentation usually occurs in immunocompromised patients, especially in those ones infected by human immunodeficiency virus (HIV). However, it is known that it might exceptionally affect individuals with normal immune response.
Case report: in this manuscript, we report a case with ocular involvement in a male immunocompetent patient. He had extended skin lesions and conjunctival hyperemia on the right eye. After the laboratorial investigation we confirmed syphilis and excluded human immunodeficiency virus (HIV) infection. Considering he had uveitis, the case was conducted as neurosyphilis.and the treatment was made with Ceftriaxone, followed by excellent clinical response.
Conclusion: given the increasing number of cases of syphilis, in patients with polymorphic skin lesions associated with systemic
symptoms, it is important to exclude immunosuppression and even in immunocompetent.subjects this condition should always be a differential diagnosis.
Keywords: Malignant Syphilis; Immunocompetent; Uveitis
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
CASE REPORT ON PEMPHIGUS FOLIACEUS
1. A CASE REPORT ON PEMPHIGUS FOLIACEUS
Presented by Krishna . M
ABSTRACT
A middle aged man presented to the dermatology clinic with an
complaint of photo distributed , burning , hyperpigmented scaling patches and
plaques involving the malar cheeks , upper chest and upper back. physicians
included pf , cutaneous lupus , erythematosus diseasein the working of the
diagnosis when patients present with sever back pain and evidence of past
history treated with CLE and seborrheic dermatitis . A biopsies , ELISA
performed examination confirmed the diagnosis of pemphigus foliaceus .
INTRODUCTION
Pemphigus foliaceus (PF) is a rareautoimmune disorder characterized
by Subcorneal acantholysis mediated by IgG anti-desmoglein-1 (DSG1)
antibodies. We encountered a case of PF in a Hispanic patient seen initially by
the emergency roomphysician. The clinical presentation of this condition is
characterized by often-thick keratotic scale on an erythematous basewith
neither bullae formation nor mucosalinvolvement, as was the casewith our
patient. Immunofluorescencepatterns and specific antibody titers help to
establish the PF diagnosis; however, thepresentation may at times overlap
significantly with other forms of pemphigus, so it is important for the
practitioner to obtain a biopsy. Thereis no Gold standard algorithm for
pemphigus management,1 and patients and physicians should be awarethat it
may be chronic and difficult to treat, requiring multiple follow up . Patients
should be informed that treatment may need to be adjusted throughoutthe
clinical courseof the disease to maintain remission.
CASE PRESENTATION
A 43 years old African American male presented to the dermatology clinic
with an 18 month history of photo distributed , burning , hyperpigmented
scaling patches and plaques involving the malar cheek , upper chest and chest
back . He had been evaluated at an outside institution and treated for CLE and
seborrheic dermatitis. Repeated biopsies from the trunk and face revealed non
specific spongiotic dermatitis on both occasions . He denied any other
2. symptoms of systemic lupus erythematous . He was tested extensively for
connective tissue disease. ANA , anti ds DNA antibody ,anti smith antibody ,
and anti-histone , antibody were all negative.
He was referred to the walter reed national military medical center
dermatology department for evaluation after severalmonths of treatment
with topical tacrolimus and fluocinonide, without resolution of his rash. Upon
examining the patient , the clinical differential included PF , Cutaneous lupus
erythematous , inflammatory seborrheic dermatitis and pemphigus
erythematous . biopsies for routine staining and DIF wereperformed . DIF
demonstrated intercellular IgG Staining in the epidermis most prominentin the
superficialepidermis , consistentwith PF . upon closer review of pervious
biopsies , focal areas of acantholysis and dyskeratosis werenoted in the
granular layer , also highly suggestiveof PF . Additionally , enzyme-linked
immunosorbentassay (ELISA)for antidesmoglein and anti desmoglein
antibodies was performed on the patient’s serum,which showed an increased
presenceof the former, supportiveof PF . After reaching a satisfactory
diagnosis, the patient began a one month courseof rituximab with marked
improvement .
Discussion
There are six major types of disorders in the pemphigus family, features of
which can overlap in the samepatient: pemphigus vulgaris, pemphigus
herpetiformis, IgA pemphigus, paraneoplastic pemphigus, drug-induced
pemphigus, and pemphigus foliaceus. Pemphigus foliaceus has three subtypes:
1) classic or sporadic PF, 2) pemphigus erythematosus, a more limited form of
the disease, and 3) endemic PF (fogo selvagem), typically seen in indigenous
South American populations. The three entities present with identical
histological findings. While pemphigus foliaceus occurs globally, the
epidemiology of the diseasecan change based on location. For example, in
Brazil, endemic PF occurs 20 times more frequently than pemphigus vulgaris.5
In a Finnish study, pemphigus erythematosus was themost common
pemphigus disorder out of 44 patients, and pemphigus vulgaris and pemphigus
foliaceus occurred at the same rate.6 A study of 148 pemphigus patients in
Turkey found that 83.1% of patients had pemphigus vulgaris, 8.8% had
pemphigus foliaceus, and 4% had pemphigus erythematosus.4 HLA
polymorphisms can be dependent on the geographic location of patients,
which may account for the regional variations in pemphigus-foliaceus
3. epidemiology. Pemphigus foliaceus is a rare immunobullous diseasethat can
have localized or diffusemanifestations. Ittypically occurs in patients aged 40
to 60 years and affects males and females equally.2 Classic features of PF
include erythematous papules and plaques with crusting, scaling and erosion,
without mucosalinvolvement, on the face, scalp and trunk, often called a
“seborrheic” distribution. Itcommonly presents as erosions demonstrating a
positive Nikolsky sign, as pemphigus vulgaris does. Patients are rarely
illappearing. The most severeform of PF presents with exfoliative
erythroderma.2 In allforms, there are detectable serum IgG antibodies against
DSG1. The primary histologic feature is subcornealacantholysis. This finding
may be indistinguishablefromthat seen in bullous impetigo, with which it
shares a common autoantigen. The key to PF diagnosis is direct
immunofluorescence(DIF) demonstrating IgG autoantibodies and C3 on the
epidermal cell surface. Pemphigus foliaceus has been associated with several
HLA polymorphisms, indicating a genetic predisposition.3 Endemic PF, also
known as fogo selvagem, presents like other PF subtypes but is most
commonly seen in Brazilian patients.11 Itis also found elsewhere in South
America as well as in Central America, Algeria, Finland, Morocco and Tunisia.5
Patients tend to be young adults who spend a good deal of time in outdoor
activities.12 The incidence of new cases increases at the end of the rainy
season.5 Thedisease tends to occur in patients of lower socioeconomic status,
and the condition improves when the living conditions improve.13 Itis
associated with IgMand IgEantibodies against DSG-1.12 Patients with endemic
pemphigus foliaceus havean association with HLA class II alleles, indicating a
possibleunderlying genetic susceptibility in these patients.14 There is evidence
that a prior antigenic responseto an environmental factor may help trigger the
DSG-1 antibodies.12 Morespecifically, patients may haveIgG1 againstDSG-1,
but the onsetof clinical disease appears to be associated with a significant rise
in IgG4.15 Thecondition typically affects the face and upper trunk. There is a
localized form, which has a good prognosis and may spontaneously remit. The
generalized formtends to be more aggressive.11 Systemic corticosteroids are
the therapy of choice for endemic PF. Pemphigus erythematosus (PE), also
known as Senear-Usher syndrome, can presentas vesicles, bullae, or scaly
plaques over seborrheic areas, the malar area, the trunk or the
extremities.3,16 PE is considered a localized form of pemphigus foliaceus. It
shares features with lupus erythematosus, including a positive ANA and
histological findings of IgG or IgM granular deposits and C3 at the
4. dermoepidermal junction.16 However, mostpatients with PE do not have
lupus erythematosus. Cases haveshown a possible link between psychiatric
disorders and pemphigus, with a recent reportof two cases of pemphigus
erythematosus associated with bipolar disorder.17 Therearealso severalcases
of thymoma associated with pemphigus erythematosus.
CONCLUSION
A 43 Years aged man presented to the dermatology clinic with an
complaint of photo distributed , burning , hyperpigmented scaling patches and
plaques involving the malar cheeks , upper chest and upper back may guide
the clinical suspension. Timely treatment of pemphigus foliaceus can avoid
extensive investigation , treatment delays and adverseeffect long term
outcomes , including compression fractures with neurological deficits.
REFERENCE
1. Tyler Vukmer, DO,* John Hassani, DO,** Adriana Ros, DO***
*Dermatology Resident, PGY3, Hackensack University Medical Center
at Palisades, NorthBergen, NJ**Hematology/Oncology Specialist, H.
Lee Moffitt Cancer Center, TampaBay, FL ***Program Director,
Dermatology Residency, Hackensack University Medical Center at
Palisades, NorthBergen, NJ
2. WWW.MDEDGE.COM